“2025 is off to a strong start for I-Mab (IMAB). Designation of givastomig as our lead program has enabled us to unlock significant value for the Company by considerably accelerating our Phase 1b program, as we work to improve the care of patients with gastric cancers, which impact more than 250,000 people globally,” said Sean Fu, PhD, Chief Executive Officer of I-Mab. “Driven by study momentum and investigator interest, we have completed patient enrollment in the first of two Phase 1b dose expansion cohorts ahead of schedule. We expect to share data on both cohorts in 1H 2026. We believe the combination of significant progress in our givastomig program, substantial cash balance, streamlined operations, and new U.S.-based business model positions I-Mab to deliver for both patients and our investors.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-Mab files $250M mixed securities shelf
- I-Mab’s Givastomig Study Accepted for ESMO GI 2025 Presentation
- I-Mab’s Transformative Year: Financial and Strategic Highlights
- I-Mab Positions for Growth with U.S. Focus and Innovative Cancer Treatments
- Promising Pipeline and Strong Financial Position Drive Buy Rating for I-Mab